November 6, 2017 — One year follow-up data from the SCOUT I Early Feasibility Study for the Mitralign Trialign System showed positive results. The data was presented by Rebecca Hahn, M.D., FASE, director of interventional echocardiography and professor of medicine at Columbia University Medical Center / New York-Presbyterian Hospital, New York, and the national principal investigator for the SCOUT I Trial, at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) conference. 

November 6, 2017 — Three-year data from the FAME 2 study show patients with coronary artery disease who underwent a percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) in combination with medical therapy had better health outcomes. This included significantly fewer major adverse cardiac events (MACE) after three years at comparable costs than patients who received medical therapy alone.

November 6, 2017 – The Centers for Medicare & Medicaid Services (CMS) has finalized a New Technology Ambulatory Payment Classification (APC) for the HeartFlow FFR-CT Analysis, a first-of-its-kind noninvasive technology that helps clinicians diagnose and treat patients with suspected coronary artery disease (CAD). Under the APC payment system, hospitals enrolled in Medicare that bill CMS for the HeartFlow FFR-CT Analysis for Medicare patients will be eligible for reimbursement at a rate of $1,450.50 for the technical component of the test. This payment rate will take effect on Jan.